Can-Fite(CANF) - 2024 Q4 - Annual Report
Can-Fite(US:CANF)2025-04-14 12:05Exhibit 99.1 Can-Fite Reports 2024 Financial Results and Clinical Update Cancer-Free Survival of 8 Years in Liver Cancer Patient Treated with Namodenoson in Prior Phase II Study Ramat Gan, Israel, April 14, 2025 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced financial results and clinical updates for the year ended December 31, 2024. Clinical & De ...